<DOC>
	<DOCNO>NCT02004886</DOCNO>
	<brief_summary>This study ass safety , tolerability glucose-lowering efficacy MK-0893 participant type 2 diabetes mellitus . The primary hypothesis MK-0893 reduce 24-hour weighted mean glucose ( WMG ) significantly placebo .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Glucose-Lowering Efficacy MK-0893 Participants With Type 2 Diabetes Mellitus ( MK-0893-005 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Type 2 diabetes Not currently antihyperglycemic agent ( AHA ) AHA monotherapy ( include treatment insulin thiazolidinediones [ i.e. , peroxisome proliferator activate receptorgamma , PPARγ agent ] ) male female nonchildbearing potential . Women must postmenopausal premenopausal document surgically sterilize A body mass index ( BMI ) &gt; 20 ≤ 40 kg/m2 History type 1 diabetes assess investigator possibly type 1 diabetes History ketoacidosis ; clinically unstable rapidly progressive diabetic retinopathy , nephropathy , neuropathy Treatment diabetes within 3 month study participation combination antihyperglycemic therapy , insulin thiazolidinediones ( e.g. , rosiglitazone pioglitazone ) oral corticosteroid medication within 2 week prior study participation , require digoxin , warfarin , warfarinlike anticoagulant , theophylline , antidysrhythmic antiseizure medication , immunosuppressant , antineoplastic agent , herbal remedy History acquire immunodeficiency syndrome ( AIDS ) human immunodeficiency virus ( HIV ) History gastrointestinal problem disorder extensive bowel gastric surgery History significant unstable cardiovascular disease History neoplastic disease History hepatic disease History seizures , epilepsy neurologic disease History myelodysplastic preleukemic disorder severe hematological disorder</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Metformin</keyword>
</DOC>